Identification of a Novel Selective Peroxisome Proliferator-Activated Receptor α Agonist, 2-Methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic Acid (LY518674), That Produces Marked Changes in Serum Lipids and Apolipoprotein A-1 Expression-Reference-Cited by-同舟云学术

Identification of a Novel Selective Peroxisome Proliferator-Activated Receptor α Agonist, 2-Methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic Acid (LY518674), That Produces Marked Changes in Serum Lipids and Apolipoprotein A-1 Expression

Published:2005-06-02 Issue:3 Volume:68 Page:763-768
ISSN:0026-895X
Container-title:Molecular Pharmacology
language:en
Short-container-title:Mol Pharmacol

Author:

Singh Jai Pal,Kauffman Raymond,Bensch William,Wang Guoming,McClelland Pam,Bean James,Montrose Chahrzad,Mantlo Nathan,Wagle Asavari

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference30 articles.

1. Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator–Activated Receptors and Liver X Receptor-α in Humans: No Alteration in Adipose Tissue of Obese and NIDDM Patients

2. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.

3. High-Density Lipoproteins: A New Potential Therapeutic Target for the Prevention of Cardiovascular Disease

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering Risperidone-Induced Lipogenesis by Network Pharmacology and Molecular Validation;Frontiers in Psychiatry;2022-04-18

2. Targeting Foam Cell Formation in Atherosclerosis: Therapeutic Potential of Natural Products;Pharmacological Reviews;2019-09-25

3. Administration of N-Acyl-Phosphatidylethanolamine Expressing Bacteria to Low Density Lipoprotein Receptor−/− Mice Improves Indices of Cardiometabolic Disease;Scientific Reports;2019-01-23

4. Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial;Diabetes Care;2018-01-03

5. Apo A-I (Apolipoprotein A-I) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits;Arteriosclerosis, Thrombosis, and Vascular Biology;2018-01